{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:04:57Z","timestamp":1788213897941,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730052"],"award-info":[{"award-number":["81730052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000970"],"award-info":[{"award-number":["32000970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duloxetine (DLX) has been approved for the successful treatment of psychiatric diseases, including major depressive disorder, diabetic neuropathy, fibromyalgia and generalized anxiety disorder. However, since the usage of DLX carries a manufacturer warning of hepatotoxicity given its implication in numerous cases of drug-induced liver injuries (DILI), it is not recommended for patients with chronic liver diseases. In our previous study, we developed an enhanced human-simulated hepatic spheroid (EHS) imaging model system for performing drug hepatotoxicity evaluation using the human hepatoma cell line HepaRG and the support of a pulverized liver biomatrix scaffold, which demonstrated much improved hepatic-specific functions. In the current study, we were able to use this robust model to demonstrate that the DLX-DILI is a human CYP450 specific, metabolism-dependent, oxidative stress triggered complex hepatic injury. High-content imaging analysis (HCA) of organoids exposed to DLX showed that the potential toxicophore, naphthyl ring in DLX initiated oxidative stress which ultimately led to mitochondrial dysfunction in the hepatic organoids, and vice versa. Furthermore, DLX-induced hepatic steatosis and cholestasis was also detected in the exposed EHSs. We also discovered that a novel compound S-071031B, which replaced DLX\u2019s naphthyl ring with benzodioxole, showed dramatically lower hepatotoxicities through reducing oxidative stress. Thus, we conclusively present the human-relevant EHS model as an ideal, highly competent system for evaluating DLX induced hepatotoxicity and exploring related mechanisms in vitro. Moreover, HCA use on functional hepatic organoids has promising application prospects for guiding compound structural modifications and optimization in order to improve drug development by reducing hepatotoxicity.<\/jats:p>","DOI":"10.1038\/s41419-022-05042-x","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T18:25:12Z","timestamp":1659378312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High-content imaging of human hepatic spheroids for researching the mechanism of duloxetine-induced hepatotoxicity"],"prefix":"10.1038","volume":"13","author":[{"given":"Juan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ann","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-6059","authenticated-orcid":false,"given":"Yunfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"5042_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra073096","volume":"358","author":"RH Belmaker","year":"2008","unstructured":"Belmaker RH, Agam G. Major Depressive Disorder. N Engl J Med. 2008;358:55\u201368.","journal-title":"N Engl J Med"},{"key":"5042_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","volume":"126","author":"Q Liu","year":"2020","unstructured":"Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134\u201340.","journal-title":"J Psychiatr Res"},{"key":"5042_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","volume":"171","author":"CS Voican","year":"2014","unstructured":"Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171:404\u201315.","journal-title":"Am J Psychiatry"},{"key":"5042_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000447034","volume":"85","author":"AF Carvalho","year":"2016","unstructured":"Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85:270\u201388.","journal-title":"Psychother Psychosom"},{"key":"5042_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40263-018-0537-1","volume":"32","author":"SB de Gage","year":"2018","unstructured":"de Gage SB, Collin C, Le-Tri T, Pariente A, B\u00e9gaud B, Verdoux H, et al. Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French National Health Insurance Database. CNS Drugs. 2018;32:673\u201384.","journal-title":"CNS Drugs"},{"key":"5042_CR6","first-page":"1187","volume":"169","author":"S Choi","year":"2003","unstructured":"Choi S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ: Can Med Assoc J = J de l\u2019Assoc Med canadienne. 2003;169:1187.","journal-title":"CMAJ: Can Med Assoc J = J de l\u2019Assoc Med canadienne"},{"key":"5042_CR7","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1177\/0960327112444477","volume":"31","author":"W Wang","year":"2012","unstructured":"Wang W, Lin R, Zhang J, Mao Y, Bu X, Ji Q, et al. Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium. Hum Exp Toxicol. 2012;31:1092\u2013101.","journal-title":"Hum Exp Toxicol"},{"key":"5042_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.clinthera.2005.08.010","volume":"27","author":"ME Hunziker","year":"2005","unstructured":"Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126\u201343.","journal-title":"Clin Ther"},{"key":"5042_CR9","first-page":"CD006533","volume":"10","author":"A Cipriani","year":"2012","unstructured":"Cipriani A, Koesters M, Furukawa TA, Nose M, Purgato M, Omori IM, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;10:CD006533.","journal-title":"Cochrane Database Syst Rev"},{"key":"5042_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41386-019-0523-4","volume":"45","author":"A Lisinski","year":"2020","unstructured":"Lisinski A, Hieronymus F, N\u00e4slund J, Nilsson S, Eriksson E. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study. Neuropsychopharmacology. 2020;45:553\u201360.","journal-title":"Neuropsychopharmacology"},{"key":"5042_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/17425255.4.3.281","volume":"4","author":"RS McIntyre","year":"2008","unstructured":"McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, Alsuwaidan M, Soczynska JK, et al. The hepatic safety profile of duloxetine: a review. Expert Opin drug Metab Toxicol. 2008;4:281\u20135.","journal-title":"Expert Opin drug Metab Toxicol"},{"key":"5042_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fpsyt.2019.00772","volume":"10","author":"MRA Muscatello","year":"2019","unstructured":"Muscatello MRA, Zoccali RA, Pandolfo G, Mangano P, Lorusso S, Cedro C, et al. Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder. Front Psychiatry. 2019;10:772.","journal-title":"Front Psychiatry"},{"key":"5042_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5414\/CPP43078","volume":"43","author":"A Suri","year":"2005","unstructured":"Suri A, Reddy S, Gonzales C, Knadler MP, Branch RA, Skinner MH. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther. 2005;43:78\u201384.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5042_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157488608784529189","volume":"3","author":"J Wernicke","year":"2008","unstructured":"Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf. 2008;3:132\u201342.","journal-title":"Curr Drug Saf"},{"key":"5042_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1365-2036.2010.04449.x","volume":"32","author":"R Vuppalanchi","year":"2010","unstructured":"Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Alimentary Pharmacol Ther. 2010;32:1174\u201383.","journal-title":"Alimentary Pharmacol Ther"},{"key":"5042_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0373-4","volume":"15","author":"ND Lin","year":"2015","unstructured":"Lin ND, Norman H, Regev A, Perahia DG, Li H, Chang CL, et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015;15:134.","journal-title":"BMC Gastroenterol"},{"key":"5042_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neulet.2013.02.076","volume":"544","author":"R Xue","year":"2013","unstructured":"Xue R, Zhang Y-P, Jin Z-L, Yuan L, He X-H, Zhao N, et al. The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor. Neurosci Lett. 2013;544:68\u201373.","journal-title":"Neurosci Lett"},{"key":"5042_CR18","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1021\/acs.chemrestox.6b00150","volume":"29","author":"VM Lauschke","year":"2016","unstructured":"Lauschke VM, Hendriks DF, Bell CC, Andersson TB, Ingelman-Sundberg M. Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. Chem Res Toxicol. 2016;29:1936\u201355.","journal-title":"Chem Res Toxicol"},{"key":"5042_CR19","first-page":"187","volume":"37","author":"KK Khadka","year":"2020","unstructured":"Khadka KK, Chen M, Liu Z, Tong W, Wang D. Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI). ALTEX-Alternatives Anim Exp. 2020;37:187\u201396.","journal-title":"ALTEX-Alternatives Anim Exp"},{"key":"5042_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17460441.2017.1271784","volume":"12","author":"MT Donato","year":"2017","unstructured":"Donato MT, Gomez-Lechon MJ, Tolosa L. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies. Expert Opin Drug Discov. 2017;12:201\u201311.","journal-title":"Expert Opin Drug Discov"},{"key":"5042_CR21","doi-asserted-by":"crossref","unstructured":"Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HH, Goldring CE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 2019;19:131\u201348.","DOI":"10.1038\/s41573-019-0048-x"},{"key":"5042_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1053\/j.gastro.2020.06.010","volume":"159","author":"MNB Ramli","year":"2020","unstructured":"Ramli MNB, Lim YS, Koe CT, Demircioglu D, Tng W, Gonzales KAU, et al. Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease. Gastroenterology. 2020;159:1471\u201386.e12.","journal-title":"Gastroenterology"},{"key":"5042_CR23","doi-asserted-by":"publisher","first-page":"1800110","DOI":"10.1002\/adbi.201800110","volume":"2","author":"J Liu","year":"2018","unstructured":"Liu J, Li R, Xue R, Li T, Leng L, Wang Y, et al. Liver Extracellular Matrices Bioactivated Hepatic Spheroids as a Model System for Drug Hepatotoxicity Evaluations. Adv Biosyst. 2018;2:1800110.","journal-title":"Adv Biosyst"},{"key":"5042_CR24","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41422-019-0242-8","volume":"29","author":"S Wang","year":"2019","unstructured":"Wang S, Wang X, Tan Z, Su Y, Liu J, Chang M, et al. Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury. Cell Res. 2019;29:1009\u201326.","journal-title":"Cell Res"},{"key":"5042_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bcpt.12631","volume":"120","author":"LJ Nelson","year":"2017","unstructured":"Nelson LJ, Morgan K, Treskes P, Samuel K, Henderson CJ, LeBled C, et al. Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity\/Metabolism and Significantly Outperform Standard HepG2\/C3A Cells for Pharmaceutical and Therapeutic Applications. Basic Clin Pharm Toxicol. 2017;120:30\u20137.","journal-title":"Basic Clin Pharm Toxicol"},{"key":"5042_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00204-014-1320-9","volume":"89","author":"SP Rebelo","year":"2015","unstructured":"Rebelo SP, Costa R, Estrada M, Shevchenko V, Brito C, Alves PM. HepaRG microencapsulated spheroids in DMSO-free culture: novel culturing approaches for enhanced xenobiotic and biosynthetic metabolism. Arch Toxicol. 2015;89:1347\u201358.","journal-title":"Arch Toxicol"},{"key":"5042_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1517\/14656566.6.5.707","volume":"6","author":"RS McIntyre","year":"2005","unstructured":"McIntyre RS, Konarski JZ. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. Expert Opin Pharmacother. 2005;6:707\u201313.","journal-title":"Expert Opin Pharmacother"},{"key":"5042_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00204-013-1034-4","volume":"87","author":"K Sinha","year":"2013","unstructured":"Sinha K, Das J, Pal PB, Sil PC. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol. 2013;87:1157\u201380.","journal-title":"Arch Toxicol"},{"key":"5042_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2:875\u201394.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5042_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.euroneuro.2012.06.001","volume":"23","author":"R Xue","year":"2013","unstructured":"Xue R, Jin ZL, Chen HX, Yuan L, He XH, Zhang YP, et al. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2013;23:728\u201341.","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"key":"5042_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/molecules22020234","volume":"22","author":"Q Liu","year":"2017","unstructured":"Liu Q, Zhu M, Geng X, Wang H, Ng TB. Characterization of polysaccharides with antioxidant and hepatoprotective activities from the edible mushroom Oudemansiella radicata. Molecules. 2017;22:234.","journal-title":"Molecules"},{"key":"5042_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/hep.24012","volume":"53","author":"Y Wang","year":"2011","unstructured":"Wang Y, Cui C-B, Yamauchi M, Miguez P, Roach M, Malavarca R, et al. Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds. Hepatology. 2011;53:293\u2013305.","journal-title":"Hepatology"},{"key":"5042_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep35434","volume":"6","author":"DFG Hendriks","year":"2016","unstructured":"Hendriks DFG, Fredriksson Puigvert L, Messner S, Mortiz W, Ingelman-Sundberg M. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Sci Rep. 2016;6:35434.","journal-title":"Sci Rep."},{"key":"5042_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.intimp.2014.05.014","volume":"21","author":"NO Al-Harbi","year":"2014","unstructured":"Al-Harbi NO, Imam F, Nadeem A, Al-Harbi MM, Iqbal M, Ahmad SF. Carbon tetrachloride-induced hepatotoxicity in rat is reversed by treatment with riboflavin. Int Immunopharmacol. 2014;21:383\u20138.","journal-title":"Int Immunopharmacol"},{"key":"5042_CR35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1021\/tx100141d","volume":"23","author":"G Wu","year":"2010","unstructured":"Wu G, Vashishtha SC, Erve JCL. Characterization of Glutathione Conjugates of Duloxetine by Mass Spectrometry and Evaluation of in Silico Approaches to Rationalize the Site of Conjugation for Thiophene Containing Drugs. Chem Res Toxicol. 2010;23:1393\u2013404.","journal-title":"Chem Res Toxicol"},{"key":"5042_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.redox.2018.09.010","volume":"20","author":"A Gille","year":"2019","unstructured":"Gille A, Turkistani A, Tsitsipatis D, Hou X, Tauber S, Hamann I, et al. Nuclear trapping of inactive FOXO1 by the Nrf2 activator diethyl maleate. Redox Biol. 2019;20:19\u201327.","journal-title":"Redox Biol"},{"key":"5042_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.tiv.2018.01.019","volume":"48","author":"J Xu","year":"2018","unstructured":"Xu J, Oda S, Yokoi T. Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. Toxicol Vitr. 2018;48:286\u2013301.","journal-title":"Toxicol Vitr"},{"key":"5042_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40139-013-0022-y","volume":"1","author":"J Massart","year":"2013","unstructured":"Massart J, Begriche K, Buron N, Porceddu M, Borgne-Sanchez A, Fromenty B. Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis. Curr Pathobiol Rep. 2013;1:147\u201357.","journal-title":"Curr Pathobiol Rep."},{"key":"5042_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jhep.2012.08.018","volume":"58","author":"T-M Leung","year":"2013","unstructured":"Leung T-M, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 2013;58:395\u20138.","journal-title":"J Hepatol"},{"key":"5042_CR40","doi-asserted-by":"publisher","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","volume":"273","author":"T Gerloff","year":"1998","unstructured":"Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998;273:10046\u201350.","journal-title":"J Biol Chem"},{"key":"5042_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000450911","volume":"35","author":"D Keppler","year":"2017","unstructured":"Keppler D. Progress in the Molecular Characterization of Hepatobiliary Transporters. Digestive Dis (Basel, Switz). 2017;35:197\u2013202.","journal-title":"Digestive Dis (Basel, Switz)"},{"key":"5042_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/jat.3711","volume":"39","author":"W Han","year":"2019","unstructured":"Han W, Wu Q, Zhang X, Duan Z. Innovation for hepatotoxicity in vitro research models: a review. J Appl Toxicol. 2019;39:146\u201362.","journal-title":"J Appl Toxicol"},{"key":"5042_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4306\/pi.2010.7.3.228","volume":"7","author":"YM Park","year":"2010","unstructured":"Park YM, Lee BH, Lee HJ, Kang SG. Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder. Psychiatry Investig. 2010;7:228\u201330.","journal-title":"Psychiatry Investig"},{"key":"5042_CR44","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.tcb.2016.03.008","volume":"26","author":"M Mattiazzi Usaj","year":"2016","unstructured":"Mattiazzi Usaj M, Styles EB, Verster AJ, Friesen H, Boone C, Andrews BJ. High-Content Screening for Quantitative Cell Biology. Trends Cell Biol. 2016;26:598\u2013611.","journal-title":"Trends Cell Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05042-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:10:31Z","timestamp":1669302631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["5042"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05042-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"669"}}